| Medical Policy | Revision |
|---|---|
| Spesolimab-sbzo (Spevigo®) “Notification” (PDF) | Added requirement for self-administration unless certain criteria are met, or the request is for the 150 mg/mL prefilled syringe to be used as a 600 mg SC loading dose. Added Site of Care medical necessity criteria. Minor adjustments made throughout policy and to formatting for clarity according to FDA label. Policy notification given 9/1/2025 for effective date 11/1/2025. |
Log In
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.